Loading stock data…
LENZ Therapeutics (LENZ)
$5.33-0.63 (-10.57%)
Market ClosedLast close Sep 8
LENZ Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
LENZ Therapeutics, Inc. in the Healthcare sector is trading at $5.33 with a market capitalization of $203M. Wall Street consensus targets $24.00 (7 analysts), implying a +350.3% move over the next 12 months. The stock is currently near its 52-week low of $4.54, remaining 53.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +350.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.90M↑ | $1.59M↓ | $12.50M↑ | $5.00M | $0 |
| Gross Profit | $825,000 | — | — | — | $0 |
| Operating Income | -$44.13M↓ | -$38.46M↓ | -$18.89M↓ | -$16.86M↑ | -$16.93M |
| Net Income | -$41.49M↓ | -$35.90M↓ | -$16.70M↓ | -$14.91M↓ | -$14.62M |
Peer Comparison
JNJUNHPFE
Fundamentals
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of pre...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$203.49M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-44.22%
Volume
Today's trading volume
641,065
Recent News
LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript
Prescription growth surged 45% in July after telehealth launch.
LENZ Therapeutics (LENZ) Stock Sees Fair Value Moves Lower After Analyst Target Cuts
The analyst fair value estimate for LENZ Therapeutics has shifted from US$32.00 to about US$26.83 per share, which now lines up more closely with the US$7 price target cluster that many firms reference. This reset reflects the more cautious stance in recent research, where several analysts cut price targets and moved to Neutral while they reassess the VIZZ launch and the company’s cash support. As you read on, you will see how these moving targets shape the evolving LENZ Therapeutics...
LENZ Therapeutics Inc (LENZ) (Q2 2026) Earnings Call Highlights: VIZZ Launch Momentum ...
Strong cash position and expanding global partnerships offset modest Q2 product revenue growth as the company scales commercial execution.
LENZ Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby summary of LENZ Therapeutics, Inc.'s Q2 2026 earnings call
LENZ Therapeutics Q2 Earnings Call Highlights
LENZ Therapeutics (NASDAQ:LENZ) reported second-quarter revenue of $5.5 million as it continued the commercial launch of VIZZ, citing modest quarterly growth and a pickup in prescription activity following the July rollout of national television advertising and a telehealth access option. Product r